<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vor Biopharma Inc — News on 6ix</title>
<link>https://6ix.com/company/vor-biopharma-inc</link>
<description>Latest news and press releases for Vor Biopharma Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vor-biopharma-inc" rel="self" type="application/rss+xml" />
<item>
<title>Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement</description>
</item>
<item>
<title>Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-doses-first-patient-in-global-phase-3-upstream-sjd-registrational-trial-of-telitacicept-in-primary-sjogrens-disease</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-doses-first-patient-in-global-phase-3-upstream-sjd-registrational-trial-of-telitacicept-in-primary-sjogrens-disease</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>First and only dual BAFF/APRIL inhibitor in primary Sjögren’s disease, one of the largest autoimmune diseases without an approved therapy BOSTON, March 30,</description>
</item>
<item>
<title>Vor Bio Announces $75 Million Private Placement with TCGX</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-dollar75-million-private-placement-with-tcgx</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-dollar75-million-private-placement-with-tcgx</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases,</description>
</item>
<item>
<title>Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-to-participate-in-the-46th-annual-td-cowen-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-to-participate-in-the-46th-annual-td-cowen-health-care-conference</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases,</description>
</item>
<item>
<title>Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-participate-44th-annual-130000735</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-participate-44th-annual-130000735</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PTLocation: The Westin St. Francis, Georgian Room A live webcast and archived replay of the presentation will be available on the C</description>
</item>
<item>
<title>Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-appoints-ra-capital-210100525</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-appoints-ra-capital-210100525</guid>
<pubDate>Tue, 23 Dec 2025 21:01:00 GMT</pubDate>
<description>BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company’s recently announced $150M PIPE financing, which included participation from both investors. “Andrew and</description>
</item>
<item>
<title>Vor Bio Announces $150 Million Private Placement</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-150-million-130000738</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-150-million-130000738</guid>
<pubDate>Mon, 15 Dec 2025 13:00:00 GMT</pubDate>
<description>BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $15</description>
</item>
<item>
<title>Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-reports-third-quarter-210100359</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-reports-third-quarter-210100359</guid>
<pubDate>Thu, 13 Nov 2025 21:01:00 GMT</pubDate>
<description>Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gross proceeds of $115 million raised in the November 2025 underwritten public offering, including the underwriters’ full exercise of the option to purchase additional shares BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatm</description>
</item>
<item>
<title>Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-pricing-public-025600249</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-pricing-public-025600249</guid>
<pubDate>Tue, 11 Nov 2025 02:56:00 GMT</pubDate>
<description>BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $10.00 per share. The gross proceeds from the offering are expected to be $100 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is</description>
</item>
<item>
<title>Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-proposed-public-210100005</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-proposed-public-210100005</guid>
<pubDate>Mon, 10 Nov 2025 21:01:00 GMT</pubDate>
<description>BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. In addition, Vor Bio intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock at the public offering price, less underwriting d</description>
</item>
<item>
<title>Vor Bio to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-participate-upcoming-investor-130000402</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-participate-upcoming-investor-130000402</guid>
<pubDate>Fri, 07 Nov 2025 13:00:00 GMT</pubDate>
<description>BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: TD Cowen Virtual Immunology & Inflammation SummitFireside Chat: Wednesday, November 12, 2025, at 2:30pm ET 8th Annual Evercore Healthcare ConferenceFireside Chat: Tuesday, December 2, 2025, 3:00pm ETLocation: Miami, FL A live webcast and archived replay of</description>
</item>
<item>
<title>Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-appoints-jeremy-sokolove-130000294</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-appoints-jeremy-sokolove-130000294</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development to the company’s leadership team. “We are thrilled to welcome Jeremy to Vor Bio,” said Jean-Paul Kress, M.D., Chie</description>
</item>
<item>
<title>Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-reports-inducement-grants-203000779</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-reports-inducement-grants-203000779</guid>
<pubDate>Fri, 31 Oct 2025 20:30:00 GMT</pubDate>
<description>BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 113,478 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 24,319 shares of Vor Bio’s common stock to 20 newly hired employees. The</description>
</item>
<item>
<title>Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-host-webcast-breaking-203000691</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-host-webcast-breaking-203000691</guid>
<pubDate>Wed, 22 Oct 2025 20:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease. The study was conducted by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331). During the webcast, Vor Bio management, joined b</description>
</item>
<item>
<title>Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-breaking-oral-120000816</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-breaking-oral-120000816</guid>
<pubDate>Fri, 17 Oct 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsored by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), which evaluated telitacicept in adults with IgA neuropathy (IgAN), will be presented as a late-breaking oral presentation at American Society of Nephrology’s (ASN) Kidney Week 202</description>
</item>
<item>
<title>Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-publication-china-120000996</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-publication-china-120000996</guid>
<pubDate>Thu, 16 Oct 2025 12:00:00 GMT</pubDate>
<description>Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF and APRIL validated as a transformative B-cell approach, highlighting telitecicept’s potential as a disease-modifying therapy for systemic lupus erythematosus BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmun</description>
</item>
<item>
<title>Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-breaking-poster-110000209</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-breaking-poster-110000209</guid>
<pubDate>Mon, 29 Sep 2025 11:00:00 GMT</pubDate>
<description>BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick</description>
</item>
<item>
<title>Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-appoints-navid-z-120000628</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-appoints-navid-z-120000628</guid>
<pubDate>Tue, 23 Sep 2025 12:00:00 GMT</pubDate>
<description>Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launchesCAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spann</description>
</item>
<item>
<title>Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-oral-presentation-201500090</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-announces-oral-presentation-201500090</guid>
<pubDate>Wed, 17 Sep 2025 20:15:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnosti</description>
</item>
<item>
<title>Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum</title>
<link>https://6ix.com/company/vor-biopharma-inc/news/vor-bio-participate-stifel-2025-201500177</link>
<guid isPermaLink="true">https://6ix.com/company/vor-biopharma-inc/news/vor-bio-participate-stifel-2025-201500177</guid>
<pubDate>Fri, 12 Sep 2025 20:15:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1Location: Virtual A live webcast and archived replay of the fireside chat will be available on the Com</description>
</item>
</channel>
</rss>